Recursion Pharmaceuticals, Inc. (BMV:RXRX)

Market Cap	33.35B -50.6%
Revenue (ttm)	1.34B +26.9%
Net Income	-11.61B
EPS	-25.94
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	13
Average Volume	2,223
Open	63.60
Previous Close	63.54
Day's Range	63.60 - 63.60
52-Week Range	58.00 - 165.50
Beta	n/a
RSI	38.54
Earnings Date	Feb 25, 2026

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to trea...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2013
• Employees: 800
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: RXRX

Financial Performance

In 2025, Recursion Pharmaceuticals's revenue was $74.68 million, an increase of 26.92% compared to the previous year's $58.84 million. Losses were -$644.76 million, 39.1% more than in 2024.

Financial numbers in USD